CCCC Live signals | Maximize Profits with Getagraph.com

SELL 114357 min ago

@ $9.20

Issued: 15 Mar 2024 @ 15:39

Return: -45.65%

Previous signal: Mar 15 - 09:44

Previous signal: Buy

Return: 0.77 %

Live Chart Being Loaded With Signals

Commentary (31 May 2024 @ 16:00):

Stats
Today's Volume	1.12M
Average Volume	1.71M
Market Cap	344.03M
EPS	$-0.000410 ( 2024-05-09 )
Next earnings date	( $-0.350 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-2.11
ATR14	$0.00700 (0.14%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-14	Mossler Mark	Buy	27 430	Stock Option (Right to Buy)
2024-02-14	Mossler Mark	Buy	18 290	Common Stock
2024-04-01	Anderson Kenneth Carl	Buy	1 389	Common Stock
2024-04-01	Dubin Glenn	Buy	1 358	Common Stock
2024-04-01	Grogan Donna Roy	Buy	1 697	Common Stock

INSIDER POWER
59.48
Last 98 transactions
Buy: 4 435 645 \| Sell: 1 001 966

Volume Correlation

Long: 0.33 (neutral)

Short: 0.51 (weak)

Signal:(52.405) Neutral

C4 Therapeutics, Inc. Correlation

10 Most Positive Correlations
OZEM	1
NBBK	0.949
ICHKX	0.942
EVCGX	0.937
MICFX	0.937
MCHFX	0.936
MMUKX	0.936
MAMA	0.932
PRCNX	0.931
EVUAX	0.928

10 Most Negative Correlations
RAY	-0.925
IIMFX	-0.914
HTOOW	-0.908
QREARX	-0.906
NWGL	-0.897
CLMB	-0.894
HDL	-0.894
AAPD	-0.886
BRLSW	-0.872
GBLMX	-0.865

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

C4 Therapeutics, Inc. Correlation - Currency/Commodity

0.29
( neutral )

0.26
( neutral )

0.00
( neutral )

-0.33
( neutral )

C4 Therapeutics, Inc. Financials

Annual	2023
Revenue:	$20.76M
Gross Profit:	$13.02M (62.72 %)
EPS:	$-2.67

FY	2023
Revenue:	$20.76M
Gross Profit:	$13.02M (62.72 %)
EPS:	$-2.67

FY	2022
Revenue:	$31.10M
Gross Profit:	$23.52M (75.65 %)
EPS:	$-2.59

FY	2021
Revenue:	$45.79M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-1.730

Financial Reports:

No articles found.

C4 Therapeutics, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

C4 Therapeutics, Inc.

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable BiDAC degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies; CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC; and earlier stage programs comprising RET degraders for the treatment of various cancers. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; and Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.